• Publications
  • Influence
Inflammatory Breast Cancer: The Disease, the Biology, the Treatment
TLDR
This review examines IBC's unique clinical presentation, pathology, epidemiology, imaging, and biology and details current multidisciplinary management of the disease, which comprises systemic therapy, surgery, and radiation therapy.
When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer.
TLDR
A critical analysis of the literature concluded that c-erbB-2 status should not be used to determine whether a woman should receive adjuvant systemic therapy (weak prognostic factor).
Inflammatory breast cancer: what we know and what we need to learn.
TLDR
Significant advances in imaging, including digital mammography, high-resolution ultrasonography with Doppler capabilities, magnetic resonance imaging, and positron emission tomography-computed tomography, have improved the diagnosis and staging of inflammatory breast cancer, but the overall 5-year survival rate for patients with IBC remains very low.
Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.
TLDR
ECD/her-2 levels are elevated in 35-40% of patients with metastatic breast cancer and are associated with a poorer prognosis in these patients, but no predictive role for ECD/HER-2 was identified, either for endocrine therapy or for anthracycline-based chemotherapy in the metastatic setting.
Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy
TLDR
Several studies indicate that neoadjuvant chemotherapy with platinum-based regimens is effective for TNBC and is thus an important treatment option.
Role of breast tomosynthesis in diagnosis of breast cancer for Japanese women.
TLDR
3DBT is a novel technique that may provide a breakthrough in solving the difficulties of diagnosis caused by parenchyma overlap for Japanese women and was superior in diagnosing lesions in form of mass, FAD, and/or architectural distortion.
Lapatinib in the Treatment of Breast Cancer
TLDR
Clinical trials showed that lapatinib is effective for patients with HER2-positive breast cancer and may be effective in patients with central nervous system metastasis that developed after trastuzumab therapy.
Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein.
TLDR
Pretreatment circulating NRP levels predict a low likelihood of benefit from HT, specifically DRO, in patients with estrogen receptor (ER)-positive and/or progesterone receptor (PgR)-positive or receptor-unknown metastatic breast cancer, even when adjusted for other known predictive factors.
Phase II evaluation of thalidomide in patients with metastatic breast cancer.
TLDR
Single-agent thalidomide has little or no activity in patients with heavily pretreated breast cancer and further studies that include different patient populations and/or combinations with other agents might be performed at the lower dose levels.
...
1
2
3
4
5
...